Park Avenue Securities’s Cytokinetics CYTK Stock Holding History

Park Avenue Securities’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Buy	+3,752	New	+$269K	﹤0.01%	1499

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Avenue Securities's CYTK Position: Q2 2026 in Review

Park Avenue Securities opened a new position in Cytokinetics (CYTK) in Q2 2026: 3,752 shares worth $320K. The stake represents ﹤0.01% of the portfolio and ranks #1499 among its holdings.

482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Park Avenue Securities held 3,752 shares of Cytokinetics worth $320K as of Q2 2026.
Cytokinetics was a new Park Avenue Securities position in Q2 2026.
Cytokinetics made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1499 holding.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.